Kyverna Therapeutics reported total assets of $219.82M and total liabilities of $54.27M for the quarter ended Jun 2026, down 3.0% year over year. This balance sheet covers 15 quarters of results from Dec 2022 through Jun 2026, standardized by Business Quant from the company’s SEC filings.
| Balance SheetBalance Sheet | Dec2022 | Mar2023 | Jun2023 | Sep2023 | Dec2023 | Mar2024 | Jun2024 | Sep2024 | Dec2024 | Mar2025 | Jun2025 | Sep2025 | Dec2025 | Mar2026 | Jun2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | |||||||||||||||
| Current Assets | |||||||||||||||
| Cash & EquivalentsCash & Equiv. | 37.74M | 39.79M | 53.43M | 22.97M | 34.65M | 224.29M | 131.62M | 104.66M | 96.62M | 56.87M | 53.44M | 34.16M | 124.09M | 32.19M | 31.81M |
| Short-term InvestmentsInvestments (Current) | 13.59M | 0.02M | 0.03M | 22.90M | 145.51M | 214.62M | 216.92M | 189.36M | 185.80M | 158.24M | 137.00M | 155.20M | 204.30M | 167.62M | |
| Cash & Current Investments | 51.32M | 39.80M | 53.46M | 22.97M | 57.54M | 369.79M | 346.24M | 321.59M | 285.98M | 242.67M | 211.68M | 171.16M | 279.29M | 236.49M | 199.43M |
| Prepaid Assets | 1.93M | 3.12M | 5.69M | 2.59M | 3.79M | 4.62M | 5.00M | 2.65M | 3.79M | 3.70M | 5.28M | 7.12M | |||
| Current Assets | 53.25M | 60.66M | 375.49M | 348.82M | 325.37M | 290.60M | 247.65M | 214.33M | 174.93M | 282.95M | 241.73M | 206.54M | |||
| Non-Current Assets | |||||||||||||||
| Construction in Progress | 0.29M | ||||||||||||||
| Property, Plant & Equipment (Net)PP&E (Net) | 2.58M | 2.33M | 2.71M | 3.37M | 3.15M | 3.35M | 2.44M | 2.16M | 1.79M | 1.55M | 1.34M | 1.33M | |||
| Long-Term Deferred Tax | 2.57M | 2.03M | |||||||||||||
| Other Non-Current Assets | 0.68M | 3.96M | 1.74M | 1.79M | 2.44M | 3.44M | 4.20M | 4.60M | 5.91M | 5.45M | 5.57M | 4.00M | |||
| Non-Current Assets | 13.67M | 14.53M | 14.50M | 14.29M | 13.82M | 14.04M | 13.00M | 12.18M | 12.23M | 10.87M | 15.30M | 13.28M | |||
| Assets | 66.92M | 75.20M | 389.98M | 363.12M | 339.20M | 304.65M | 260.66M | 226.51M | 187.16M | 293.83M | 257.02M | 219.82M | |||
| Liabilities | |||||||||||||||
| Current Liabilities | |||||||||||||||
| Accounts Payables | 1.45M | 4.36M | 7.45M | 4.86M | 9.93M | 4.62M | 8.47M | 9.92M | 3.02M | 5.31M | 11.60M | 2.93M | |||
| Payables | 1.45M | 4.36M | 7.45M | 4.86M | 9.93M | 4.62M | 8.47M | 9.92M | 3.02M | 5.31M | 11.60M | 2.93M | |||
| Other Accumulated Expenses | 0.57M | 1.79M | 3.08M | 5.78M | 6.43M | 2.90M | 1.76M | 1.23M | 2.04M | 2.17M | 3.02M | 4.00M | |||
| Current Leases | 1.08M | 0.96M | 0.98M | 1.00M | 0.93M | 0.78M | 0.51M | 0.29M | 0.19M | 0.31M | 0.22M | 0.13M | |||
| Total Current Liabilities | 11.95M | 19.86M | 21.87M | 23.48M | 30.99M | 33.76M | 33.29M | 39.79M | 33.87M | 36.49M | 29.67M | 22.80M | |||
| Non-Current Liabilities | |||||||||||||||
| Capital Leases | 0.92M | 0.67M | 0.41M | 0.24M | 0.14M | 0.07M | 0.03M | 0.01M | |||||||
| Non-Current Debt | 24.74M | 24.81M | 24.88M | ||||||||||||
| Preferred Stock Liabilities | 120.67M | 120.67M | 145.73M | 180.57M | 180.57M | ||||||||||
| Non-Current Deferred Tax LiabilityNon-Current Deferred Tax | -2.57M | -2.03M | |||||||||||||
| Operating Leases | 7.21M | 5.24M | 6.46M | 5.72M | 4.97M | 4.16M | 3.28M | 2.32M | 1.33M | 0.32M | 6.96M | 6.59M | |||
| Other Non-Current Liabilities | 0.01M | 0.22M | 0.30M | ||||||||||||
| Total Non-Current Liabilities | 140.92M | 88.12M | 36.19M | ||||||||||||
| Total Liabilities | 140.92M | 88.33M | 28.99M | 29.61M | 36.49M | 38.06M | 36.65M | 42.13M | 35.21M | 61.55M | 61.44M | 54.27M | |||
| Shareholder's Equity | |||||||||||||||
| Total Debt | 24.74M | 24.81M | 24.88M | ||||||||||||
| Common Equity | -74.00M | -84.61M | -97.20M | -111.81M | -13.14M | 360.99M | 333.51M | 302.71M | 266.59M | 224.01M | 184.38M | 151.95M | 232.28M | 195.58M | 165.55M |
| Liabilities and Shareholders Equity | 66.92M | 75.20M | 389.98M | 363.12M | 339.20M | 304.65M | 260.66M | 226.51M | 187.16M | 293.83M | 257.02M | 219.82M | |||
| Retained Earnings | -75.68M | -136.04M | -162.74M | -191.54M | -226.03M | -263.52M | -308.20M | -350.24M | -387.02M | -424.83M | -464.60M | -502.90M |
Pull Kyverna Therapeutics's standardized financial statements into your own models, spreadsheets and apps with the Business Quant Financial Statements API. The request below follows the statement, frequency and period selected above. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/statements?ticker=KYTX&statement=BS&frequency=Quarter&period=all&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/statements"
params = {"ticker": "KYTX", "statement": "BS", "frequency": "Quarter", "period": "all", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/statements?ticker=KYTX&statement=BS&frequency=Quarter&period=all&api_key=YOUR_API_KEY");
const data = await res.json();